www.lilly.co.uk

Eli Lilly and Company Limited
Lilly House
Priestley Road
Basingstoke
Hampshire
RG24 9NL

Tel: +44 (0) 1256 315000

HTA and Health Outcomes

Medical and Product Information: +44 (0) 1256 315999

20 May 2013

Meindert Boysen
Programme Director, Centre for Health Technology Evaluation
National Institute of Health and Clinical Excellence
10 Spring Gardens
London
SW1A 2BU

Dear Meindert

Dapagliflozin in combination therapy for the treatment of type 2 diabetes [ID427]
Lilly Response to Appraisal Consultation Document (ACD)

Eli Lilly and Company Ltd appreciates the opportunity to review and comment on the appraisal consultation document (ACD) for Dapagliflozin in combination therapy for the treatment of type 2 diabetes.

Eli Lilly supports the development of new technologies which provide individual treatment choices and a patient-centred approach to diabetes management.

With regard to the specific questions posed in the ACD, we have no comments to make.

Yours sincerely

[redacted]